Virtus ETF Advisers’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-24,069
Closed -$379K 485
2024
Q1
$379K Buy
24,069
+3,463
+17% +$53.3K 0.2% 202
2023
Q4
$332K Sell
20,606
-854
-4% -$10.9K 0.21% 204
2023
Q3
$273K Sell
21,460
-2,773
-11% -$38.3K 0.17% 212
2023
Q2
$341K Buy
24,233
+4,840
+25% +$69.3K 0.2% 165
2023
Q1
$300K Buy
19,393
+341
+2% +$5.69K 0.16% 213
2022
Q4
$312K Sell
19,052
-2,692
-12% -$43.8K 0.16% 246
2022
Q3
$402K Buy
21,744
+317
+1% +$4.97K 0.16% 230
2022
Q2
$282K Buy
+21,427
New +$236K 0.1% 271
2021
Q4
Sell
-12,686
Closed -$431K 402
2021
Q3
$431K Sell
12,686
-1,160
-8% -$37K 0.19% 160
2021
Q2
$507K Buy
13,846
+2,867
+26% +$111K 0.21% 144
2021
Q1
$492K Buy
10,979
+298
+3% +$13.9K 0.21% 149
2020
Q4
$610K Buy
10,681
+5,003
+88% +$297K 0.25% 109
2020
Q3
$291K Sell
5,678
-781
-12% -$38.3K 0.15% 231
2020
Q2
$386K Buy
6,459
+887
+16% +$47.4K 0.18% 215
2020
Q1
$229K Sell
5,572
-799
-13% -$44.4K 0.09% 270
2019
Q4
$397K Sell
6,371
-5,422
-46% -$258K 0.06% 257
2019
Q3
$400K Sell
11,793
-656
-5% -$19.4K 0.08% 188
2019
Q2
$281K Buy
12,449
+1,871
+18% +$43.8K 0.06% 247
2019
Q1
$246K Sell
10,578
-1,195
-10% -$31.3K 0.52% 79
2018
Q4
$247K Buy
11,773
+355
+3% +$8.73K 0.04% 162
2018
Q3
$442K Sell
11,418
-8,377
-42% -$310K 0.05% 146
2018
Q2
$779K Buy
+19,795
New +$583K 0.69% 44

Other funds holding DCPH

Virtus ETF Advisers's DCPH Position: Q2 2024 in Review

Virtus ETF Advisers sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 24,069 shares — an estimated $379K sold.

Virtus ETF Advisers first reported a position in DCPH in Q2 2018 and held it in 22 quarters. The position peaked at $779K in Q2 2018. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

  • Virtus ETF Advisers reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 24,069 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $379K.
  • Virtus ETF Advisers first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
  • Virtus ETF Advisers's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $779K in Q2 2018.
  • 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Virtus ETF Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.